FMTX - Dosing underway in Forma Therapeutics' study of FT-7051 in prostate cancer

The first patient has been dosed in Forma Therapeutics' (FMTX) Phase 1 clinical trial evaluating FT-7051, a selective inhibitor of CBP/p300, a known co-activator of the androgen receptor in men with metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 will evaluate safety and tolerability, preliminary anti-tumor activity (PSA and radiographic responses), and pharmacokinetics/pharmacodynamics (PK/PD) of FT-7051 in men with mCRPC who have progressed despite prior therapy and have been treated with at least one potent anti-androgen therapy.

For further details see:

Dosing underway in Forma Therapeutics' study of FT-7051 in prostate cancer